Skip to main content

Medications for Mantle Cell Lymphoma

Mantle cell lymphoma is a rare form of non-Hodgkin's lymphoma that develops from mature B lymphocytes that are from a region of the lymph nodes called the 'mantle zone'. Symptoms can include swollen lymph glands, fever, night sweats, fatigue and unexplained weight loss. There may also be abdominal swelling due to enlargement of the liver or spleen.

Drugs used to treat Mantle Cell Lymphoma

The medications listed below are related to or used in the treatment of this condition.

Drug name Rating Reviews Activity ? Rx/OTC Pregnancy CSA Alcohol
Calquence
8.5 4 reviews for Calquence to treat Mantle Cell Lymphoma Rx N
Generic name:
acalabrutinib systemic
Drug class:
BTK inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
FDA approval date:
October 31, 2017
rituximab
Off-label
7.5 2 reviews for rituximab to treat Mantle Cell Lymphoma Rx C N
Generic name:
rituximab systemic
Drug class:
antirheumatics, CD20 monoclonal antibodies
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
Off-label:
Yes
Brukinsa
8.8 4 reviews for Brukinsa to treat Mantle Cell Lymphoma Rx N
Generic name:
zanubrutinib systemic
Drug class:
BTK inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
FDA approval date:
November 14, 2019
Revlimid
Rate Add review Rx ✕ N
Generic name:
lenalidomide systemic
Drug class:
miscellaneous antineoplastics, other immunosuppressants
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
FDA approval date:
December 28, 2005
acalabrutinib
7.7 7 reviews for acalabrutinib to treat Mantle Cell Lymphoma Rx N
Generic name:
acalabrutinib systemic
Brand name:
Calquence
Drug class:
BTK inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
Velcade
Rate Add review Rx D N
Generic name:
bortezomib systemic
Drug class:
proteasome inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
FDA approval date:
May 13, 2003
zanubrutinib
8.9 7 reviews for zanubrutinib to treat Mantle Cell Lymphoma Rx N
Generic name:
zanubrutinib systemic
Brand name:
Brukinsa
Drug class:
BTK inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
lenalidomide
Rate Add review Rx ✕ N
Generic name:
lenalidomide systemic
Brand name:
Revlimid
Drug class:
miscellaneous antineoplastics, other immunosuppressants
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
bortezomib
Rate Add review Rx D N
Generic name:
bortezomib systemic
Brand names:
Velcade, Boruzu
Drug class:
proteasome inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
Jaypirca
6.0 1 review for Jaypirca to treat Mantle Cell Lymphoma Rx N
Generic name:
pirtobrutinib systemic
Drug class:
BTK inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
FDA approval date:
January 27, 2023
pirtobrutinib
7.0 2 reviews for pirtobrutinib to treat Mantle Cell Lymphoma Rx N
Generic name:
pirtobrutinib systemic
Brand name:
Jaypirca
Drug class:
BTK inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
Breyanzi
Rate Add review Rx N
Generic name:
lisocabtagene maraleucel systemic
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
FDA approval date:
May 30, 2024
lisocabtagene maraleucel
Rate Add review Rx N
Generic name:
lisocabtagene maraleucel systemic
Brand name:
Breyanzi
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
methotrexate
Off-label
Rate Add review Rx ✕ N ✕
Generic name:
methotrexate systemic
Drug class:
antimetabolites, antirheumatics, antipsoriatics, other immunosuppressants
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
Off-label:
Yes
cyclophosphamide
Rate Add review Rx D N
Generic name:
cyclophosphamide systemic
Brand name:
Frindovyx
Drug class:
alkylating agents
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
cytarabine
Off-label
Rate Add review Rx D N
Generic name:
cytarabine systemic
Drug class:
antimetabolites
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
Off-label:
Yes
brexucabtagene autoleucel
Rate Add review Rx N
Generic name:
brexucabtagene autoleucel systemic
Brand name:
Tecartus
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
doxorubicin
Off-label
Rate Add review Rx D N
Generic name:
doxorubicin systemic
Drug class:
antibiotics/antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
Off-label:
Yes
Tecartus
Rate Add review Rx N
Generic name:
brexucabtagene autoleucel systemic
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
FDA approval date:
July 24, 2020
mitoxantrone
Off-label
Rate Add review Rx D N
Generic name:
mitoxantrone systemic
Drug class:
antibiotics/antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
Off-label:
Yes
vincristine
Off-label
Rate Add review Rx D N
Generic name:
vincristine systemic
Drug class:
mitotic inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
Off-label:
Yes
Boruzu
Rate Add review Rx D N
Generic name:
bortezomib systemic
Drug class:
proteasome inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
FDA approval date:
September 5, 2024
Frindovyx
Rate Add review Rx D N
Generic name:
cyclophosphamide systemic
Drug class:
alkylating agents
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information

Frequently asked questions

View more FAQ

Legend

Rating For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).
Activity Activity is based on recent site visitor activity relative to other medications in the list.
Rx Available for purchase by prescription only.
OTC Available for purchase over-the-counter.
Rx/OTC Available for purchase by prescription or over-the-counter.
Alcohol The medication interacts with alcohol (if marked with "✕").
New approval The FDA has approved this medication within the past year.
Off-label The FDA may not approve this medication for the treatment of this condition.
EUA An Emergency Use Authorization (EUA) allows the FDA to authorize unapproved medical products or unapproved uses of approved medical products to be used in a declared public health emergency when there are no adequate, approved, and available alternatives.
Expanded access Expanded access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
Pregnancy Category
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
B Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
C Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
D There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
✕ Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use in pregnant women clearly outweigh potential benefits.
N FDA has not classified the drug.
Controlled Substances Act (CSA) Schedule
M The drug has multiple schedules. The schedule may depend on the exact dosage form or strength of the medication.
U CSA Schedule is unknown.
N Is not subject to the Controlled Substances Act.
1 Has a high potential for abuse. Has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use under medical supervision.
2 Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence.
3 Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence.
4 Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3.
5 Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer